Kizhakkedathu Lab Develops Heparin Reversal Treatment Without Usual Side-Effects

Published in Blood, Dr. Manu Kalathottukaren showed that the Universal Heparin Reversal Agent (UHRA) developed in Dr. Kizhakkedathu's Lab is non-toxic and has many advantages over the current standard of treatment.


CBR Researchers Achieve near Atomic Resolution of Salmonella’s Nano-Syringe

How do pathogenic bacteria manipulate host cells and cause disease? Published in Nature, Dr Strynadka’s lab at CBR solved the structure of the “nano-syringe” Salmonella uses to infect the host and cause disease.


Hancock Lab Develops a New Tool for Studying Chlamydia Infection

While the pathological findings of the study will indeed be beneficial to antibiotic development, it is the innovative approach used in creating the in vitro model that must be highlighted.


Solving the Mystery: Heparin-induced Thrombocytopenia Without Heparin?

Heparin use is not without consequence as its usage can result in an auto-immune clotting disorder, called heparin-induced thrombocytopenia (HIT). Interestingly, HIT can persist even after heparin has cleared from the body – a mystery that the CBR researchers aimed to solve.


Novel Coating Layer to Prevent Medical Device Infections

Dr. Kai Yu developed the best performing medical device coating for preventing catheter-associated urinary tract infections.


Bee Research in the ‘omics Era: Unlocking a Troublesome Genome

Today, bees are facing many challenges, such as parasites and pesticides, and modern ‘omics technology has emerged as an excellent tool to help disentangle how complex interacting factors are affecting bee health.


Can Blood Bag Texture Affect Transfusion Safety?

Narges Hadjesfandiari discovered a simple way to significantly improve platelet transfusion safety, which will impact patients who suffer from low platelet levels that happen in severe trauma, serious infections, and cancer.


Stressing the Bugs: New Treatment Targets for Multidrug Resistant Bacteria

Sarah Mansour and her colleagues in the Hancock lab discover that resistant abscesses can be treated by targeting the bacterial response to stress.


Drop the Knife!

Patients with Inflammatory Bowel Disease (IBD) require surgery at least once in their life time. However, Bernard Lo, a PhD candidate in the research group led by CBR Principal Investigator Kelly McNagny, finds a therapeutic method to block fibrotic processes in IBD.


Researchers develop new weapon for hard-to-treat bacterial infections

Researcher Bob Hancock made an important discovery in the fight against superbugs, while his team was looking for a solution to abscesses, a condition where patients develop reoccurring fluid-filled pockets that don’t respond well to traditional antibiotic treatments.

Comments are closed, but trackbacks and pingbacks are open.